Tepmetko 225mg Tablet

• Treatment of Non-small cell lung cancer

Side effects are undesirable symptoms that can result from any medical treatment. Like any other medicine, Tepmetko 225mg Tablet       also causes some adverse impact on the body, most of which resolve without any medical attention.

Some common side effects include:

• Peripheral edema
• Nausea
• Low albumin level in blood
• Diarrhea
• Increased creatinine level in blood

Seek medical attention in case of any unusual or severe side effects immediately.

• The recommended dose Tepmetko 225mg Tablet may vary according to the type & stage of cancer, or age, weight, and other health factors of the patients. This capsule should be swallowed as a whole with water and do not crush, chew, or open it.
• It is usually taken once a day, with or without food, at a fixed time each day. Don't miss a dose or double the dose to compensate for the missed dose.​
  

• Tepmetko 225mg Tablet is an anticancer medicine. This tablet belongs to a group of medications called tyrosine kinase inhibitors works by blocking the action of the abnormal protein that is responsible for the uncontrolled growth of cancerous cells.
• It effectively slows down the progression of cancer by controlling the multiplication of cancer cells.​
  

• Wu, Y. L., Guarneri, V., Voon, P. J., Lim, B. K., Yang, J. J., Wislez, M., ... & Kim, T. M. (2024). Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial. The Lancet Oncology, 25(8), 989-1002. https://pubmed.ncbi.nlm.nih.gov/39089305/
• Le, X., Paz-Ares, L. G., Van Meerbeeck, J., Viteri, S., Galvez, C. C., Smit, E. F., ... & Paik, P. K. (2023). Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B. Cell Reports Medicine, 4(11). https://pubmed.ncbi.nlm.nih.gov/37944528/
• Wu, Y. L., Cheng, Y., Zhou, J., Lu, S., Zhang, Y., Zhao, J., ... & Bui, L. (2020). Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. The Lancet Respiratory Medicine, 8(11), 1132-1143. https://pubmed.ncbi.nlm.nih.gov/32479794/
• Mazieres, J., Paik, P. K., Garassino, M. C., Le, X., Sakai, H., Veillon, R., ... & Thomas, M. (2023). Tepotinib treatment in patients with MET exon 14–skipping non–small cell lung cancer: Long-term follow-up of the VISION phase 2 nonrandomized clinical trial. JAMA oncology, 9(9), 1260-1266. https://pubmed.ncbi.nlm.nih.gov/37270698/
• Paik, P. K., Felip, E., Veillon, R., Sakai, H., Cortot, A. B., Garassino, M. C., ... & Le, X. (2020). Tepotinib in non–small-cell lung cancer with MET exon 14 skipping mutations. New England Journal of Medicine, 383(10), 931-943.